Leukocyte Depletion of Autologous Whole Blood (LDAWB-2001)

June 9, 2008 updated by: Heidelberg University

Leukocyte Depletion of Autologous Whole Blood: Impact on Perioperative Infection Rate and Length of Hospital Stay for Hip Arthroplasty Patients

Leukocyte depletion of autologous whole blood prior to storage does not reduce infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay but may increase retransfusion perioperatively during hip arthroplasty and allogenic transfusion rate

Study Overview

Detailed Description

Informed Consent Form:

Prior to the first blood donation, in- and exclusion criteria should be tested. Then the patient is to inform by the investigator about the studies aim and participation conditions such as methods, risks, assurance, data security, etc. The patient and the investigator should sign the informed consent form.

Randomization:

If all inclusion criteria are well given and exclusion criteria are absent, the patient could be enrolled and randomized, prior to the first PAD. Enrollment is parallel in all centers until the final number of 1088 is reached. Breaking the seal of the provided randomization envelope with computerized randomization codes completes randomization. Time and date should be noted.

Blinding:

Randomization is done by the investigator, which should manage the blood donation. The blood bags after inline leukocyte depletion prior to storage do not look different from not depleted bags and are labeled only with the patient's identity and the subjects ID. The allocation to the group is to keep secret from patient, surgeon and anesthesiologist.

Treatment:

A PAD:

Group 1 Preoperative Donation of multiple units ( more than 2) 450 mL autologous whole blood and storage without leukocyte depletion Usual criteria and methods of PAD are used according to regional guidelines of blood donations in the respective center.

Group 2 Preoperative Donation of multiple units (more than 2) 450 mL autologous whole blood and storage following leukocyte depletion 2 to 4 hours after whole blood donations, the whole blood bags should be in-line filtered by the use of leukocyte filtration sets (provided by Pall Medical Company). Storage as in group 1 at 4 degree C in a blood fridge.

A as proposal, the Mannheim concept reveals a 95 percent security in avoidance of allogenic transfusions for a blood loss of 20-25 ml per kg body weight: Intended are 3 donations in weekly intervals. If Hb plasma con-tent decreases below 11 g/dL, the donation will be postponed to the fol-lowing week. Surgery is at the fifth week after the first donation.

B Anesthesia and Surgery:

As usual in the center, and without a difference between the two groups anesthesia and surgery should be performed under following aspects:

  • At hospital admission, the actual history should be taken, study measures (Appendix 1) and screening laboratory should be withdrawn prior to anesthesia to compute the infection risk assessment of the respective patient 13.
  • Both general and regional (spinal or epidural anesthesia) can be performed
  • Normothermia of the patients is essential to the infection rate, hypothermia increases the infection rate by every degree! The intra- and postoperative core temperature range will be requested.
  • Circulatory monitoring should be performed according to the centers conventions. Monitoring with a 5 channel ECG is suggested. Normovolemia is essential because hypovolemia is related to increased infection rate by hypoperfusion of the wound14-16. Therefore, a central venous catheter is useful but not obligatory, but urine output is required since it is a more sensitive volume indicator in absence of significant heart and renal failure (and common practice in hip surgery). An arterial line is not obligatory required.
  • Bladder catheter (Urine production more than 1ml/kg KG/h)
  • Cell Savers and hemodilution (iso- or hypervolemic) are not accepted.
  • Blood loss is to calculate carefully by subtracting rinsing from suction volumes and weighing sponges and drapes intraoperatively. Postoperatively the drainage volumes are sufficient if not massive expansion of thighs or hip occurs ( however, this should be noted as AE).
  • In the case that allogenic transfusion is required additionally, this should be leukodepleted.
  • Intra- und postoperative transfusion trigger are similar for autologous and allogenic transfusion:
  • Hb greater than 8,5 plus minus 0,5
  • HF over 100 plusminus 10 /min or 35% above base line
  • MAP below 60 plusminus 5 mmHg or 35% below base line
  • Stenocardia, chest pain
  • ST-segment changes greater than 0,2 ms

Further documentation of

  • ASA
  • sex
  • weight
  • height
  • Anesthesia duration
  • OP-duration
  • Blood loss(intra- and postoperatively)
  • Lowest diastole. RR intraoperatively as well as postoperatively POD 0
  • Time of transfusions
  • Time of urine catheter withdrawal Infection-Monitoring

Parameter:

• Skin inspection

Criteria of wound infection:

  • secretion clear or pus,
  • pos. bacterial culture,
  • erythema

    • Urine culture if indicated by sediment (at withdrawl of bladder cathe-ter, discolored urine or fever)
    • Blood culture (if fever above 39°C after POD2)
    • Tracheal secretion (if expectoration is prutride or radiological indica-tion of bronchopneumonia)
    • Antibiotic treatment, duration, amounts, multidrug use

Woundhealing and the occurrence of infections were classified with the ASEPSIS score: Of influence is the duration of antibiotic treatment, drainage of pus, wound de-bridements, erythema, involvement of deeper tissue layers, identification of bacteria, LOS above 14 days 17.

Infection Definition

Occurrence of any infection is defined as

  • Elevation of patient's temperature/fever above 38°C on POD 3 or later or
  • Leukocytosis above the cut off point (generated for every individual subject )or
  • BSG / CRP above the cut off point (generated for every individual subject ) or
  • Isolation of bacteria from any fluid including pus or
  • Abscess (verificated by surgical drainage or ultrasonographically guided aspiration of pus ) or
  • Arthritis by local clinical symptoms and surgical drainage

Wound infection is assessed by the ASEPSIS score

Urinary tract infection is defined as

  • new isolated occurrence of leukocytosis, and/or nitrite, and/or protein or
  • isolation of bacteria more than 10 000/µl (sediment) or
  • growth of more than 100 000 colonies of a single organism in the culture

Respiratory airway infection is defined as

  • positive x-ray (chest infiltrate) and fever or
  • dyspnea or cough or purulent sputum and fever or
  • isolation of bacteria in tracheal secretion (only intubated subjects) and fever

Septicemia is defined as

• clinical symptoms and positive blood culture

Study Type

Interventional

Enrollment (Actual)

1089

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Marburg, Germany, 35043
        • Institute of Transfusion Medicine and Hemostasiology, University of MArburg
    • Baden-Wuerttemberg
      • Mannheim, Baden-Wuerttemberg, Germany, 68167
        • Clinic of Anesthesiology and Critical Care Medicine, Faculty of Clinical Medicine MAnnheim, University of Heidelberg, Germany
    • Bavaria
      • Garmisch Partenkirchen, Bavaria, Germany, 82467
        • Klinikum Garmisch Partenkirchen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • • ASA I-III,

    • Age 18-85 years,
    • Body weight 50-125 kg
    • If female, with either a history of an accepted method of anticonception for at least 3 month prior and 1 month following the termination of the study or climacteric or with a negative betA- HCG-Test in urine or serum.
    • Preoperative blood donation of at least 2 units (450mL whole blood)
    • Preoperative hemoglobin level > 10 mg/dL
    • Able and willing to sign informed consent

Exclusion Criteria:

  • Subjects with a contraindication for preoperative blood donation (PAD) (in 12, PP 36-43).

    • systemic infection
    • acute bacterial or viral diseases
    • anemia (Hb > 11g/dL)
    • myocardial infarction within the past 6 month,
    • instable angina pectoris
    • vascular stenosis (i.e. of the coronary or internal carotid arteries)
    • hemodynamic relevant valvular stenosis
    • heart failure > NYHA II
    • history of strokes or TIA
    • steroid therapy,
    • immune deficiency,
    • hematological or endocrinological disease,
    • coagulopathy,
    • history of organ transplantation,
    • simultaneous participation in a second study
    • pregnancy
    • membership at Jehovah's Witnesses
    • intended use of a cell saver

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: 1
storage and transfusion of autologous whole blood without leukocyte depletion : Control group
Experimental: 2
storage and transfusion of leukocyte depleted autologous whole blood : leukocyte depletion group
leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours
Other Names:
  • Fresenius leukocyte depletion whole blood filters

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Comparison of infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay
Time Frame: 90 days
90 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Blood loss and transfusion rate
Time Frame: 90 days
90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Thomas Frietsch, MD, PhD, Clinic of Anesthesiology and Critical Care Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2001

Primary Completion (Actual)

April 1, 2005

Study Completion (Actual)

September 1, 2005

Study Registration Dates

First Submitted

September 11, 2005

First Submitted That Met QC Criteria

September 12, 2005

First Posted (Estimate)

September 15, 2005

Study Record Updates

Last Update Posted (Estimate)

June 10, 2008

Last Update Submitted That Met QC Criteria

June 9, 2008

Last Verified

June 1, 2008

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sepsis

Clinical Trials on leukocyte depletion of whole blood

3
Subscribe